Join Now

Utah Life Sciences News & Events

EVŌQ Bio is Fielding Partnership Inquiries for its Antimicrobial Medical Materials Additives at the MedTech Conference

October 13, 2022

 Attendance at premiere medical technology convention to spur partnership, growth opportunities.

SALT LAKE CITY, October 10, 2022 /PRNewswire/ – EVŌQ Bio (an EVŌQ Nano company), a nano-platform technology company, is pleased to announce their attendance at the MedTech Conference 2022 in Boston, Massachusetts October 24-26, 2022. The MedTech Conference is the premiere venue for executives from across the medical device and technology industry to share the latest advancements and create partnerships. 

EVŌQ Bio has developed EVQ-218, a nanotherapeutic that shows broad spectrum activity against fungi, gram-negative and gram-positive bacteria without developing drug resistance. In vitro testing at Seattle Children’s Research Institute and animal studies at Lovelace Biomedical has confirmed efficacy against 60+ strains of multi-drug resistant bacteria while exhibited no toxicity at therapeutic doses. Third party minimum inhibitory concentration and biofilm inhibitory concentration testing demonstrated comparable or improved outcomes against leading antibiotics. EVŌQ Bio will be using this opportunity to take meetings on the many uses of EVQ-218 as an antimicrobial additive to a variety of potential applications. 

“Infections related to surgical and medical devices continue to rise, demanding new solutions,” said David Nilson, Vice President of EVŌQ Bio. “Our novel technology has been shown to radically reduce the onset of bacteria colonization and biofilm formation on inserted and implanted devices, thus decreasing the number of nosocomial infections. The broad-spectrum activity of our technology shows efficacy against staph, E. coli, pseudomonas, burkholderia and all NTM strains tested.” 

In addition to medical devices, EVŌQ Bio’s poly-therapeutic platform leverages nano-technology in the development of antimicrobial applications, including a pulmonary therapeutic to treat bacterial lung disease. 

EVŌQ Bio’s attendance at Medtech seeks to develop partnerships to bring this technology to multiple device and supply manufacturers. EVŌQ Bio will be fielding meeting requests throughout the event via in-person requests and the Medtech Partnering Platform. 

About EVŌQ Bio 

EVŌQ Bio (an EVŌQ Nano, Inc company) is a nano-technology platform company developing early-stage pharmaceutical research and medical device applications to reduce the global threat of multi-drug resistant infections. Our technology and unique mechanism of action enables treatment and prevention of bacterial disease, without contributing to the growing list of drug-resistant pathogens. 


Media Contact

Zach Jacob

Director of Marketing, EVŌQ Nano